Department of Obstetrics & Gynaecology, Dalhousie University, Halifax, Nova Scotia, Canada.
Department of Obstetrics & Gynaecology, IWK Health Centre, Halifax, Nova Scotia, Canada.
PLoS One. 2020 Jan 10;15(1):e0227245. doi: 10.1371/journal.pone.0227245. eCollection 2020.
To compare effectiveness and safety of oral misoprostol (50 μg every four hours as needed), low dose vaginal misoprostol (25 to 50 μg every six hours as needed), and our established dinoprostone vaginal gel (one to two mg every six hours as needed) induction.
Consenting women with a live term single cephalic fetus for indicated labor induction were randomized (3N = 511). Prior uterine surgery or non-reassuring fetal surveillance were exclusions. Concealed computer generated randomization was stratified and blocked. Newborns were assessed by a team unaware of group assignment. The primary outcome was time from induction at randomization to vaginal birth for initial parametric analysis. Sample size was based on mean difference of 240 minutes with α2 = 0.05 and power 95%. Non-parametric analysis was also pre-specified ranking cesareans as longest vaginal births.
Enrollment was from April 1999 to December 2000. Demographics were similar across groups. Analysis was by intent to treat, with no loss to follow up. Mean time (±SD) to vaginal birth was 1356 (±1033) minutes for oral misoprostol, 1530 (±3249) minutes for vaginal misoprostol, and 1208 (±613) minutes for vaginal dinoprostone (P = 0.46, ANOVA). Median times to vaginal birth were 1571, 1339, and 1451 minutes respectively (P = 0.46, Kruskal-Wallis). Vaginal births occurred within 24 hours in 44.9, 53.5 and 47.7% respectively (P = 0.27, χ2). There were no significant differences in Kaplan Meier survival analyses, cesareans, adverse effects, or maternal satisfaction. The newborn who met birth asphyxia criteria received vaginal misoprostol, as did. all three other newborns with cord artery pH<7.0 (P = 0.04, Fisher Exact).
There was no significant difference in effectiveness of the three groups. Profound newborn acidemia, though infrequent, occurred only with low dose vaginal misoprostol.
比较口服米索前列醇(50μg,按需每四小时一次)、小剂量阴道米索前列醇(25-50μg,按需每六小时一次)和我们已建立的地诺前列酮阴道凝胶(1-2mg,按需每六小时一次)引产的有效性和安全性。
符合条件的足月单胎头位孕妇进行引产,随机分为 3 组(n=511)。子宫手术史或胎儿监护不典型者排除。采用隐藏式计算机生成的随机化方法,按分层和块进行分组。新生儿的评估由一个不知道分组的团队进行。主要结局是从随机分组到阴道分娩的时间,进行初始参数分析。样本量基于 240 分钟的平均差异,α2=0.05,效能 95%。非参数分析也预先指定了剖宫产术的最长阴道分娩排名。
入组时间为 1999 年 4 月至 2000 年 12 月。各组的人口统计学特征相似。分析采用意向治疗,无失访。口服米索前列醇组阴道分娩的平均时间(±SD)为 1356(±1033)分钟,阴道米索前列醇组为 1530(±3249)分钟,阴道地诺前列酮组为 1208(±613)分钟(P=0.46,方差分析)。阴道分娩的中位时间分别为 1571、1339 和 1451 分钟(P=0.46,Kruskal-Wallis 检验)。分别有 44.9%、53.5%和 47.7%的患者在 24 小时内阴道分娩(P=0.27,χ2检验)。Kaplan-Meier 生存分析、剖宫产术、不良反应或产妇满意度无显著差异。符合新生儿窒息标准的新生儿接受了阴道米索前列醇治疗,其他 3 名脐动脉 pH 值<7.0 的新生儿也接受了治疗(P=0.04,Fisher 确切概率法)。
三组之间的有效性无显著差异。尽管罕见,但严重的新生儿酸中毒仅发生在小剂量阴道米索前列醇组。